glp 1 agonist mechanism of action weight loss GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Glucagon-like peptide 1 receptor agonists:

In consideration of the reduced compliance of peptide GLP-1 receptor agonists due to subcutaneous injection, oral micromolecular GLP-1 receptor agonists such as orforglipron have already in clinical trials, which can reduce body weight and improve cardiac metabolism in adults with obesity (Wharton et al 2023) (Fig

Cartoon images were created using BioRender

Most required prior authorization

National Institute of Health (NIH), after analyzing weights and cardiovascular, metabolic risk factors a year after suspending the Wegovy treatment, patients regained two-thirds of the lost weight on average, and their cardiovascular, metabolic risk factors also returned to similar levels to changed weights

This is important because GLP-1 drugs were originally designed to have a long half-life in blood to maximise their efficacy in the treatment of diabetes which prevents them from entering the brain (Hlscher)

R., Tschp, M